Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q3 2025 · 10-Q
Revenue$8.76M$8.76M−28.8% vs Q3 2024 Net Income$911.00K$911.00K−45.6% vs Q3 2024 EPS Diluted$0.03$0.03−92.1% vs Q3 2024 Gross Profit$5,439,000−31.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,938,000−8.4% Free Cash Flowderived$1,821,000+14.2% Margins · derivedGross margin62.1%−2.2 pt vs Q3 2024
Operating margin13.1%−5.6 pt vs Q3 2024
Net margin10.4%−3.2 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 12, 2025 · 43 d after period end